Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at

Share Article

In-demand research report “Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight” created by FirstWord is now available at

TD The Market Publishers Ltd

Combination therapy, or polytherapy, will likely become the leading treatment option for chronic obstructive pulmonary disorder (COPD) as the dominant companies like the UK’s GlaxoSmithKline plc and AstraZeneca plc as well as Germany’s Boehringer Ingelheim compete with each other for market share and position. But will market payers, clinicians and patients be disposed to change from the already well-entrenched products to completely new ones?

In spite of recently approved dual combinations of long-acting beta2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) introducing little novelty to the therapeutic party, firms kept on attaching prime significance to combination approaches. The main focus area for companies today is on triple combination products, which are expected to simplify sequencing for COPD therapy and offer adherence benefits. But do KOLs agree?

In-demand research report “Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight” created by FirstWord is now available at

Report Details:

Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
Published: April, 2015
Price: US$ 7,495.00

The research study presents opinions from the top 12 US and European KOLs, presents expert insights for the branded pharma manufacturing sector and the drug discovery community. The report highlights the KOLs’ ideas about present-day treatment options, alongside discussions on what novel therapies will have to demonstrate for the treatment paradigm for COPD to change.

Reasons to Buy:

  •     Know the extensive opinions of KOLs and elaborate efficient product positioning and clinician communication strategies.
  •     Outline novel treatment methods to COPD patients and patient subgroups
  •     Discover patient characteristics and product attributes which the KOLs believe are key to prescribing decisions
  •     Find out which clinical trials the KOLs think will likely considerably influence prospective treatment decisions and their possible outcomes
  •     Assess the dynamic and challenging competitive scenario in the marketplace.

More new reports by the publisher can be found at FirstWord page.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Natalie Aster
Follow >
Like >
Follow us on